Short Interest in Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Drops By 51.8%

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 70,094 shares, a decline of 51.8% from the August 15th total of 145,548 shares. Based on an average daily trading volume, of 53,172 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.3% of the shares of the company are short sold.

Serina Therapeutics Stock Performance

Shares of NYSEAMERICAN SER traded down $0.19 during midday trading on Wednesday, hitting $2.16. 21,475 shares of the stock traded hands, compared to its average volume of 61,398. The firm has a 50-day moving average of $2.39 and a two-hundred day moving average of $2.07. The firm has a market capitalization of $54.86 million, a P/E ratio of -1.14 and a beta of 1.18. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.65 and a current ratio of 6.65. Serina Therapeutics has a one year low of $1.22 and a one year high of $5.83.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its earnings results on Thursday, August 13th. The company reported ($0.55) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of Serina Therapeutics in a research note on Thursday, September 10th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Serina Therapeutics has an average rating of “Buy” and an average target price of $8.00.

About Serina Therapeutics

Serina Therapeutics, Inc is a clinical-stage biotechnology company developing medicines for chronic diseases. The company uses its proprietary POZ polymer technology to modify therapeutic molecules with the goal of extending their duration of action, potentially reducing dosing frequency and improving treatment convenience.

Serina’s lead product candidate is SER-252, also known as POZ-apraglutide, a long-acting version of the peptide apraglutide. The company is evaluating the candidate as a potential treatment for short bowel syndrome with intestinal failure and other conditions in which enhanced intestinal absorption may be beneficial.

The company’s development programs are based on its POZ platform, which is designed to control the release and circulation of attached drug compounds.